Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Mazdutide

A Study of IBI362 in Participants With Obesity or Overweight

Innovent · Phase 3 · Completed · Enrollment 610

NCT05607680

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Placebon/rn/rn/rn/r
IBI362 4 mgn/rn/rn/rn/r
IBI362 6 mgn/rn/rn/rn/r

Not shown

  • Placebo: endpoint not reported
  • IBI362 4 mg: endpoint not reported
  • IBI362 6 mg: endpoint not reported